Title: Cabozantinib in progressive medullary thyroid cancer
Authors: Elisei, Rossella ×
Schlumberger, Martin J
Müller, Stefan P
Schöffski, Patrick
Brose, Marcia S
Shah, Manisha H
Licitra, Lisa
Jarzab, Barbara
Medvedev, Viktor
Kreissl, Michael C
Niederle, Bruno
Cohen, Ezra E W
Wirth, Lori J
Ali, Haythem
Hessel, Colin
Yaron, Yifah
Ball, Douglas
Nelkin, Barry
Sherman, Steven I #
Issue Date: Oct-2013
Publisher: Grune & Stratton
Series Title: Journal of Clinical Oncology vol:31 issue:29 pages:3639-46
Article number: 10.1200/JCO.2012.48.4659
Abstract: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.
ISSN: 0732-183X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science